Archives

BioStock published an article on 5 May 2021 about Aptahem, which can be read in full below. Biotechnology company Aptahem, which is developing the preclinical drug candidate Apta-1 for the [...]

BioStock published an article on 24 March 2021 about Aptahem, which can be read in full below. Aptahem is developing the drug candidate Apta-1 as an emergency treatment for sepsis, a [...]

BioStock published an article on 10 March 2021 about Aptahem, which can be read in full below. Aptahem announced yesterday that the company has entered into a non binding Term Sheet (NBTS) with a [...]

Aptahem AB (publ) announce today that the company has signed an NBTS (non binding Term Sheet) with a mid-sized pharmaceutical company with head quarters in Europe. The NBTS relates to license [...]

Aptahem AB (publ) announce today that the company has signed an agreement with their collaboration partner LGC Group to initiate the GMP (Good Manufacturing Practice) manufacturing of Apta-1. [...]

Aptahem AB (publ) announce today that the company has received patent approval in India for patent family 1, with patent application number 6250/DELNP/2010. The patent, with the patent number [...]

BioStock published an article on 22 December 2020 about Aptahem, which can be read in full below. Aptahem, which is developing an emergency medicine for the treatment of sepsis, carried out an [...]

BioStock published an article on 8 December 2020 about Aptahem, which can be read in full below. Aptahem, whose primary drug candidate Apta-1 is being developed as an emergency treatment [...]

BioStock published an article on 26 November 2020 about Aptahem, which can be read in full below. Biotechnology company Aptahem, that develops its drug candidate Apta-1 for the treatment of [...]

Aptahem AB (publ), announce today that the company enters a collaboration agreement with the German company Granzer Regulatory Consulting and Services to prepare for applications to the European [...]